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Tumor metastasis is the dominant cause of death in cancer patients. However, the
molecular and cellular mechanisms underlying tumor metastasis are still elusive.
The identification of protein molecules with their expressions correlated to the
metastatic process would help to understand the metastatic mechanisms and thus
facilitate the development of strategies for the therapeutic interventions and clini-
cal management of cancer. Proteomics is a systematic research approach aiming to
provide the global characterization of protein expression and function under given
conditions. Proteomic technology has been widely used in biomarker discovery
and pathogenetic studies including tumor metastasis. This article provides a brief
review of the application of proteomics in identifying molecular factors in tumor
metastasis process. The combination of proteomics with other experimental ap-
proaches in biochemistry, cell biology, molecular genetics and chemistry, together
with the development of new technologies and improvements in existing method-
ologies will continue to extend its application in studying cancer metastasis.
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Tumor Metastasis
Although diagnostic technology and therapeutic
treatment have made vast progress during the last
decades, cancer mortality remains high, accounting
for approximately 25% of the deaths in the developed
world (1 ). Metastasis is by far the leading cause of
death in cancer patients, responsible for more than
90% of all cancer mortality (2 ). Tumor metastasis
is the spread of cancer cells from the original site to
other parts of the body. It is a very complex and
multi-step process and often referred to as a cascade.
The process of metastasis formation begins with some
tumor cells breaking adhesions with neighboring cells
and detaching from the primary tumor. Those cells
then dissolve the extracellular matrix, migrate and
invade surrounding tissues, and/or travel via the cir-
culatory system, invade, survive and proliferate at dis-
tant new sites (3 ).
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Questions to be answered in metastasis
Histological evidence suggests that metastatic tumor
is made up of the same type of cells as the primary
tumor. It is obvious that those successful metastatic
cells must have a set of particular characteristics that
are different from non-metastatic tumor cells, en-
abling them to complete each step in the metastatic
sequence. Perhaps it is these particular characteristics
that make metastatic cancer more resistant to treat-
ment than primary tumor even using the most ag-
gressive chemotherapy or radiotherapy (4 ). However,
how do metastases arise from primary tumors? What
are the underlying molecular and cellular mechanisms
in cancer progression? What characteristics does the
metastatic tumor possess? Answers to these questions
are clearly of considerable importance not only for the
understanding of the tumor behavior but also for the
clinical treatment of cancer. Aiming at those ques-
tions, researchers have been looking for events and
factors that may influence tumor dissemination and
hoping to provide useful clues for developing more ef-
fective approaches to counter the disseminated cancer.
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Molecular factors involved in metastatic
process
Many molecular factors have been reported to be re-
lated to the formation of detectable metastases. Cell
adhesion molecules, members of the cadherin families,
integrins, and several other cell adhesion molecules
including CD44 and the 67–69 kDa laminin-elastin
binding protein, have been identified as modulators
of metastatic growth (3 ). The proteolytic enzymes
including metalloproteinases, uPA/uPAR system as
well as the cysteine proteases appear to be crucial for
the development of distant organ metastasis (3 ). The
emerging role of angiogenesis and lymphangiogenesis
in invasion and metastasis has also been recognized
to be important for tumor cell dissemination (5 ).
In addition, a number of genes have been found in-
volved in each stage of the metastatic cascade. Onco-
genes are a group of factors that have been implicated
in the metastatic process (6 ). For example, activating
mutations in the Ras and the activation of the Raf-
mitogen activated protein kinase 1/2 pathway can re-
sult in a metastatic phenotype in a variety of cell types
(7 , 8 ). The ectopic expression of other oncogenes in-
cluding the MET, serine/threonine kinases Mos and
Raf, tyrosine kinases Src, Fms and Fes also induces
the metastatic phenotype in recipient cells (9 , 10 ).
In contrast, some genes have been described as
suppressors of metastasis, bearing abilities to inhibit
metastatic cascade at different stages. Most of these
genes consistently suppress metastasis without affect-
ing proliferation in vitro or primary tumor size in
vivo (11 ). Among these genes Nm23 is the most in-
teresting one. Steeg compared the expression level
of the genes in seven cell lines derived from the
same parental melanoma cell line K-1735 with widely
varied metastatic potentials (12 ). The expression
of Nm23 cDNA was found quantitatively reduced
in five highly metastatic cell lines as compared to
two related less metastatic cell lines. So far, twelve
metastasis-suppressor genes have been described (12 ).
In a recent Cell paper, Yang and colleagues showed
that TWIST—a master gene that controls epithelial–
mesenchymal transition in embryogenesis—was re-
quired for metastasis in epithelial-derived breast tu-
mors (13 ). TWIST is a gene regulator, instructing
genes when to turn on and turn off. Researchers com-
pared the levels of TWIST expression in metastatic
and non-metastatic human breast cancer cell lines and
showed that only metastatic lines expressed TWIST.
As pointed out by the authors, “TWIST is probably
the first gene regulator that has been tied so defini-
tively to human cancer metastasis” (13 ). By looking
at TWIST gene’s on or off, the potential of tumor
invasion and metastasis can be estimated.
Up to date, most metastasis studies have been
focusing on single genes, or at most, small groups
of genes in an experimental model. For instance,
researches using genetically engineered mice usually
involve the over-expression or mutation of a single
gene. Although vast amounts of information have
been gleaned from these studies, they rarely accu-
rately represent the complex milieu of genetic interac-
tions in cancer metastasis in a global sense. In addi-
tion, it is widely accepted that the invasion and metas-
tasis formation not only depend on the metastatic ca-
pacity of tumor cells but also tightly correlate with
surrounding stroma and infiltrating tissues. The re-
cently emerging systematic technologies enable us to
investigate thousands of RNA expression levels simul-
taneously and to identify patterns associated with the
biological characteristics of metastasis.
Studies of metastasis by DNA microar-
ray
Several recent analyses of human tumor metastasis
using DNA microarrays have obtained exciting infor-
mation that strongly challenge classic metastasis hy-
pothesis. Studies have shown that a gene set was
highly correlated with patient’s outcome, and pri-
mary tumors can be classified into those with “good”
or “poor” prognoses based on their patterns of gene
expression (14 , 15 ). Van’t Veer et al used DNA
microarray to analyze 117 young patients with pri-
mary breast tumor and identified a set of 70 genes
strongly predicting metastatic potential, which are
called “poor prognosis signature” (14 ). More re-
cently, a small set of 17 genes was reported to predict
metastatic potential for a variety of solid tumors (16 ).
These results are in conflict with generally accepted
progression model that predicts a series of random
mutations within a primary tumor to generate a small
subpopulation that acquires full metastatic capability.
However, both the conflicting hypotheses can have
their supporting and opponent evidence (11 , 17 , 18 ).
A research article published in Cancer Cell may help
to reconcile these two models: evidence showed that
highly metastatic variants do exist in the bulk tumor
population and these highly metastatic variants do
have a “metastatic signature” (19 ). Based on these
results, the metastasis paradox may be resolved by
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combining the two hypotheses: metastatic potential
is determined early in oncogenesis but primarily by
host genetic background, on which specific mutations
occur to promote metastasis (20 ).
The cDNA microarray analysis has been fruitful
in identifying genes that are altered in expression (6 )
and a set of genes that may be the “metastatic signa-
ture” (14 , 16 ) in some kinds of tumors. However, it
is clear that the functional endpoint of the genetic
blueprint lies at the protein level, in the forms of
signaling networks and protein interaction maps that
make up the circuitry within the cell since cell func-
tion is directly regulated through proteins but not
through genes or messenger RNA (21 ). Cellular be-
haviors such as normal growth and differentiation are
influenced by a large number of protein molecules and
depend on the presence of appropriate proteins in the
right context. Through signal transduction cascades
and transcriptional networks, alterations of proteins
can affect a large number of cellular pathways and
result in global effects on cell behaviors. Regulation
of translation and post-translational modification of
proteins such as proteolytic processing, phosphorlya-
tion, or glycosylation clearly play significant roles in
determining cellular functions. Therefore, gene find-
ings in cancer progression and invasion still need to be
validated at protein levels. Furthermore, proteins are
primary targets and therapeutic molecules in pharma-
ceuticals. Thus, it is of vital importance to globally
identify changes in protein expression in disease states
including metastasis.
Proteomics
Traditionally, analysis of the proteins coded by genes
was performed on a single protein at a time. The
technologies to identify and quantitate proteins on a
global scale are not as robust as those available for ge-
nomics. As biology enters the post-genomic era, the
near completion of human genome sequencing coupled
with the technical progress made in protein identifi-
cation has created new opportunities for proteomic
analysis, characterizing and investigating proteins in
a systematic manner.
Principle of proteomics
The term “proteome” was coined in 1994 and de-
fined as the entire protein complement expressed by
a cell line, tissue, or organism. Proteomics is the
study of the proteome and a natural successor to ge-
nomics (22 ). Collectively, proteomics can be defined
as the study of all proteins, including their relative
abundance, distribution, post-translational modifica-
tions, functions, and interactions with other macro-
molecules, in a given cell or organism within a given
environment and at a specific stage in the cell cy-
cle. Proteomics can be classified into several differ-
ent sub-disciplines. Recent studies on tumor metas-
tasis mainly concentrated on “profiling/expression”
and “functional” proteomics (23 ). Profiling or ex-
pression proteomics focuses on the description of the
whole proteome in a given tissue, body fluid or cell,
including organelle mapping and differential measure-
ment of protein expression levels in cells and/or un-
der different conditions. In a review by MacBeath et
al (24 ), profiling proteomics was descried as “unbi-
ased” or “discovery-oriented proteomics” because in-
vestigators cannot impose their knowledge of biology
on the experimental design and both known and un-
known proteins may be identified in such an experi-
ment. Functional proteomics can be thought as “fo-
cused” or “system-oriented proteomics” (24 ). It is a
research approach that directly analyzes a subset of
proteins, such as a family of sequence- or function-
related proteins, and characterizes the protein biolog-
ical functions, protein-protein or protein-DNA/RNA
interactions, and protein post-translational modifica-
tions.
Methodology of proteomics
A number of complimentary technologies have been
developed to analyze proteins on a global scale. Cur-
rently, the most commonly used proteomic plat-
forms include protein separation coupled with mass
spectrometry (MS) and protein microarray methods
(23 , 25 ).
MS analysis in proteomics
MS is an analytical technique that can be used to
identify unknown compounds. In the past ten years,
this technology matured rapidly due to the invention
of two ionization techniques—electrospray ionization
(ESI) and matrix-assisted laser desorption/ionization
(MALDI) that enable proteins and peptides to be ion-
ized at high sensitivity without excessive fragmenta-
tion. This invention led John Fenn and Koichi Tanaka
to be awarded the 2002 Nobel Prize in Chemistry
(26 ). Sample ionization by a laser and detection as
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ion mass to charge (m/z) ratio with a mass analyzer
are two basic steps in MS. MALDI ion sources are
most commonly coupled with time of flight (TOF)
mass analyzer, whereas ESI is most often coupled with
ion-trap or triple-quadrupole MS/MS spectrometer.
In MALDI-TOF MS, peptides derived from prote-
olytic digested proteins are ionized from a plate into
the spectrometer, and the m/z ratios of peptides are
measured based on the length of time for the peptides
to move in a vacuum tube to reach a detector, and
then a list of mass spectra are produced. By apply-
ing database search algorithms, MS spectra are then
matched to calculate masses in a sequence database,
resulting in identification of target proteins. This type
of protein identification method is known as peptide
mass fingerprinting (PMF; ref. 27 ). MALDI-TOF
and PMF are usually coupled with two-dimensional
gel electrophoresis (2DE) techniques in proteomics.
Tandem mass spectrometry (MS/MS) can be
thought as a two-stage MS experiment. At the first
stage, peptides are ionized and separated by m/z. A
peptide of interest is selected and allowed to pass into
a collision cell for further fragmentation. Resulting
sequential m/z values are determined in a second MS
analyzer to generate a MS/MS spectrum, representing
a series of ion fragments of the specific peptide (28 ).
A partial amino acid sequence is then constructed ac-
cording to the MS/MS spectrum. As compared with
PMF, the specificity of MS/MS-based protein identifi-
cation is often higher because it provides information
not only about peptide masses but also peptide se-
quences.
Protein separation
Protein separation methods can be classified as gel-
based and non-gel based approaches. 2DE is a clas-
sical protein separation technology. In fact, for many
years it has been considered synonymous with “pro-
teomics” because of its ability to separate thousands
of proteins at a time. In 2DE, proteins extracted from
cells or tissues are separated according to their isoelec-
tric points (pIs) in the first dimension and their molec-
ular weights in the second dimension (28 ). After vi-
sualizing by Coomassie blue or silver staining or other
fluorescent dye, each observed protein spot is quan-
tified by its staining intensity. It has been reported
that up to 2,000 spots can be detected in a single gel
with advanced visualizing methods. Besides its high
resolution, 2DE can resolve post-transcriptionally or
proteolytically modified proteins from their “parent”
molecules. It has been demonstrated that in a 2D-gel
up to a quarter of the spots visualized are modified
proteins (29 , 30 ). The ability of 2DE to directly de-
termine abundance of proteins in analyzed samples
enables 2DE to become a major tool in expression
proteomics. Actually, since 2DE was first described in
1969 and refined by Klose and O’Farrell (28 ), its ap-
plication in protein separation and comparative anal-
ysis has occurred long before the global differential
analysis of mRNA, and many of the 2DE principles
are commonly used in the systematic quantitative
analysis of gene expression patterns (27 ). However,
it was not until the technological advances in MS and
bioinformatics for protein identification that 2DE be-
came a major technique in proteomics.
Liquid chromatography (LC) is another usually
used protein separation approach. It has been shown
that this method can successfully resolve the mix-
ture of proteins and allow the isolation of individual
proteins based on a particular biochemical property.
Some commonly used LC columns include size ex-
clusion LC, ion exchange LC, and reverse-phase LC.
For more complete analysis or analysis of very com-
plex protein mixtures, 2D chromatography strategies
can be employed (31 ). In the first dimension, pro-
teins are separated by size-exclusion or cation ex-
change chromatography and in the second dimension
by reverse-phase HPLC. Followed by MS measure-
ment and database searching, the fractionated pro-
teins can be directly analyzed. This is often referred
as “shotgun” proteomics strategy (32 ). The “shot-
gun” method shows advantages over gel-based tech-
niques in speed, sensitivity, scope of analysis and dy-
namic range and it could be amenable to automation.
Unfortunately, LC/MS is not capable of determining
protein abundance. The emergency of isotope-coded
affinity tagging approach (ICAT) adds a quantitative
dimension to MS/MS (27 ). The cysteine residues in
a pair of samples are labeled with d0- and d8-ICAT
reagents respectively. The samples are then combined
and analyzed by LC-MS/MS. Each cysteinyl peptide
appears as a pair of signals differing by the mass dif-
ferentially encoded in the mass tag. The ratio of these
signal intensities precisely indicates the ratio of abun-
dance of the protein from which the peptide originates
and the MS/MS spectrum of the peptide allows the
protein to be identified.
Protein microarray
Protein microarray can be considered to be analogous
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to DNA microarrays. Affinity reagents such as an-
tibodies, nucleic acids and lipids are arrayed at high
spatial density on a solid support and then probed
with compounds of interest (24 ). Currently there are
two types of protein microarrays: abundance-based
microarray and function-based microarray (33 ), en-
abling researchers to interrogate simultaneously the
abundance and function of many different proteins
with minimal sample consumption (34 ). Antibody
microarrays have been used to screen for potential
biomarkers in cancer tissues (35 ) and human blood
serum (36 ) in parallel because of their relatively high
specificity and extreme sensitivity. Depending on
the individual affinities of the immobilized antibodies,
antigens can be detected in picomolar (pM) concen-
trations. In reverse phase protein microarray, sample
proteins or peptides are immobilized in a miniaturized
format and are used for probing with known binding
molecules. This method allows the parallel analysis of
multiple biological samples and thus is best suited to
clinical practice. Protein microarray also provides a
well-controlled in vitro way to study protein function,
including protein-protein, protein-lipid and protein-
nucleic acid interactions on a genome-wide basis (37–
40). This approach has demonstrated a huge applica-
tion potential in “focused proteomics”. However, to
obtain highly specific and stable capture molecules is
a major challenge in the array-based proteomics. For
example, considering the specificity, affinity and cross-
reactivity, only about 5% (24 )–30% (41 ) of commer-
cial antibodies are suitable for microarray-based anal-
yses. So far, the most successful protein microarray
assays are those directed towards cytokines because
there are many antibodies to cytokines for choices
(42 ).
A special case of the protein array is the sur-
face enhanced laser desorption ionization (SELDI)-
ProteinChip. SELDI-ProteinChip system is an evolv-
ing proteomics platform that allows rapid and sen-
sitive analysis of complex protein mixtures stemmed
from body fluids, cells, and/or tissues at the femto-
mole level (43 ). The chip surfaces are chemically or
biochemically modified to be able to capture a cer-
tain group of proteins based on their specific physical
and chemical properties. The surface properties of the
protein chips include weak cation exchange, strong an-
ion exchange, immobilized metal affinity chromatog-
raphy, reverse phase and normal phase, as well as bio-
chemical affinities allowing proteins or antibodies to
be bound directly to the chip (28 ). Samples such as
serum or protein extracts are applied to the surface,
incubated, and washed to remove non-bound proteins
and contaminants. The retained proteins are then an-
alyzed in a mass spectrometry to generate proteomic
profiles. The great advantages of this approach are
its sensitivity to analyze small amounts of raw protein
samples and its ability to detect proteins with molec-
ular weights lower than 6 kDa. These characteristics
make SELDI-ProteinChip technology very suitable for
biomarker discovery. However, SELDI is not a quan-
titative approach and protein identification cannot be
directly determined through this method (44 ). Nev-
ertheless, protein microarrays and chips probably con-
stitute the most promising technologies for the future
development of cancer proteomics.
Application of Proteomics in
Studying Tumor Metastasis
There are two main expected outcomes from pro-
teomic analysis of tumor metastasis. The first is to
discover new molecular markers from the profiling of
metastatic tumors. The second is to decipher the in-
tracellular signaling pathways that lead cancer cells to
be metastatic. Expression and functional proteomics
are respectively suited for the purposes of the metas-
tasis studies. The resulting data would provide knowl-
edge bases for the early detection and prediction of
metastasis and for the identification of novel targets
for drug development and therapeutic intervention.
Expression proteomics
Considering that cell behavior is ultimately reflected
by actual protein contents within cells, protein expres-
sion patterns of certain tissues or cells in a given dis-
ease state will have complicated changes that should
contain important information about the pathologic
process taking place in the cells. The presence and/or
the amount alteration of a particular protein may not
only serve as a potential biomarker but also provide
insights into the basic etiology of disease. Most of the
proteomic analyses for tumor metastasis use expres-
sion proteomics (Table 1). 2DE followed by protein
identification using MS and PMF is the most mature
platform for large-scale analysis of proteins directly
from biological samples (45 ). By comparing protein
expression profiles of clinical specimens obtained from
primary and metastatic tumors or cell lines originated
from the same parental cell line but with different
metastatic potency, researchers may discover and
156 Geno. Prot. Bioinfo. Vol. 2 No. 3 August 2004
Cai et al.
Table 1 Summary of Representative Proteomic Studies in Cancer Metastasis
Tumor Samples Methods Ref.
Expression Breast cancer Tumor interstitial fluid; 2DE, MS 92
proteomics Highly metastatic MDA-MB-435 cells and
metastasis-suppressed BRMS1-transfected MDA-
MB-435 cells;
2DE, MS 72
A pair of monoclonal cell lines from the human
breast carcinoma cell line MDA-MB-435 that have
different metastatic phenotypes;
LC/LC-MS 67
Plasma membrane proteome of the metastatic
MDA-MB-435 cells.
2DE, MS 93
Colorectal Primary and metastatic tumor tissues; 2DE, MS 46
carcinomas Laser-microdissected cells from normal and malig-
nant colonic epithelium and stroma;
LCM, SELDI 61
Normal tissue, adenoma, carcinoma and metastasis. 2DE, MS 50
prostate cancer Androgen-stimulated prostate cancer cells; 2DE, MS 94
Dunning prostate cancer cell lines with variable
metastatic potential;
SELDI 95
Conditioned medium of PC3 cells. 2DE, MS 96
Gastric cancer Gastrointestinal stromal tumor tissue; 2DE, MS 51
Normal, cancer and metastases tissues. 2DE, MS 49
Lung cancer Highly and poorly metastatic sublines (PLA801D
and PLA801C);
2DE, MS 48
Bronchial epithelial immortalized cells and malig-
nant transformation cells.
2DE, MS 97
Head and
neck tumor
UMSCC10A and UMSCC10B cell lines derived from
primary tumor and a metastatic lymph node of the
same patient respectively;
2DE, MS,
SELDI
55
Laser-microdissected cryostat sections from tumors
and adjacent mucosa.
LCM, SELDI,
2DE
60
human salivary
gland adenoid
cystic carcinoma
Poorly metastatic Acc-2 cell line and highly
metastatic Acc-M cell line.
2DE, MS 52
Hepatocellular
carcinoma
Hepatocellular carcinoma cell lines Hep3B,
MHCC97L, MHCC97H with different metasta-
sic potential.
2DE,
LC-ESI-MS/MS
47
Functional
proteomics
Colon cancer Antisense uPAR cDNA transfected and mock-
transfected HCT116 cells.
2DE, MS 68
Breast cancer Adriamycin resistant cell line MCF-7/ADR and
metastatic cell line MDA-MB;
2DE, MS 53
Mammey cells transfected and/or stimulated by
growth factors.
2DE, MS 56
Ovarian cancer Laser-microdissected cells from ovarian tumor tis-
sues.
LCM, reverse-
phase protein
array technology
76
Lymphosarcoma Canine lymphosarcoma tissue. RPLC, MS 98
Enzyme activity A panel of Breast cancer cell lines and melanoma
cancer cell lines.
Activity-based
protein profiling
37
Fibrosarcoma HT-1080 fibrosarcoma cells. Functional pro-
teomic screens
99
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identify differentially expressed proteins that may be
associated with cancer progression and metastasis for-
mation.
Colon cancer is one of the highly metastatic
tumors. To find out proteins over-expressed in
metastatic colonic adenocarcinomas, Tachibana et
al compared the protein profiles of primary and
metastatic tumors by 2DE and found a number of
protein spots that appeared in metastatic tumor in
liver but not in primary tumor (46 ). One of these
spots was identified by MS as apolipoprotein A1, sug-
gesting that the expression of apolipoprotein A1 may
be associated with colonic adenocarcinoma progres-
sion and the protein may be a potential marker for
the aggression of the cancer. Cui and colleagues per-
formed the comparative study to differentiate the pro-
tein expression profiles of several hepatocellular carci-
noma cell lines with various metastatic potentials and
found that there were 16 proteins over-expressed and
10 proteins under-expressed in metastatic cell lines
(47 ). Two proteins, annexin-1 and S100A4, were be-
lieved to be the key molecules related to hepatocellu-
lar carcinoma metastasis and recurrence. Other stud-
ies also showed that proteins including annexin-1 were
significantly up-regulated in a highly metastatic lung
cancer cell line (PLA810D) compared to the poorly
metastatic cell line (PLA810C) (48 ). These results
suggested that annexin-1 may play a role in tumor
metastasis. Similar comparative studies were also car-
ried out with other kinds of tumor tissues (49–51)
and cancer cell lines (52–55). These proteomic data
are valuable and informative for understanding tumor
metastasis.
However, due to the limitation of 2DE technol-
ogy, it is impossible to survey all of the changes in
protein expression for a given tissue in a certain dis-
ease state. This is because a typical 2DE gel can
only separate and detect about 1,000–2,000 proteins,
much less than the number of proteins expressed in
cells (56 ). Some proteins, such as high hydrophobic
membrane proteins, low soluble proteins, and proteins
with extreme molecular sizes and pIs, may not be de-
tectable by 2DE. Low abundance proteins are lost in
2DE analysis. A study by Gygi et al indicated that
up to 75% of cell proteins were below the protein de-
tection limit of 2DE (57 ). In addition, there are prob-
lems associated with reproducibility and visualization
methods (58 ). Refinements in the technique are cur-
rently being developed to address each of these prob-
lems. For example, the use of narrow-range immo-
bilized pH gradient strips and pre-fractionation can
greatly improve the 2DE resolution (58 ). Removal
of high abundance proteins before 2DE can increase
the chances of identification of low-abundance pro-
teins. For those highly complex and heterogeneous
tissue samples, laser capture microdissection (LCM)
can be used for the procuring and enriching subpop-
ulations of cells prior to sample preparation for 2DE
proteomic analysis (44 ). The development of fluores-
cent dye labels allowing proteomic comparison of two
samples on a single gel, referred as difference gel elec-
trophoresis (DIGE), not only improves the detection
sensitivity but provides more accurate quantification
and spot statistics (59 ).
As a complementary approach, SELDI-
ProteinChip technology has also been utilized for
protein profiling in studying tumor metastasis. In
comparison, SELDI-ProteinChip has a number of ad-
vantages over 2DE, including less amount of sample
requirement, better reproducibility, improved identi-
fication for proteins at extremes of pIs, and greater
sensitivity and accuracy for detecting low-molecular-
weight proteins. By combining SELDI-ProteinChip
technology with LCM and immunohistochemistry,
Melle and co-workers have successfully identified and
characterized head and neck tumor-related biomark-
ers (60 ). They firstly detected differentially expressed
proteins in head and neck tumors using ProteinChip
technology, subsequently enriched and identified the
proteins of interest by 2DE and MS, and finally found
that proteins S100A8 (calgranulin A) and S100A9
(calgranulin B) may be responsible for invasion and
metastasis. Krieg et al also used SELDI-TOF-MS
to analyze the protein profiles of colonic epithelium
and stroma cells and found that three peptides were
increased in the colon tumor epithelium and stroma
compared to normal colon and stroma in nine patients
(61 ). The study demonstrated that 500–1,000 cells
were enough to do the comparative protein profiling
by SELDI-ProteinChip technology. Serum proteomics
analysis has recently been shown to be an effective
means to detect early or recurrent malignancy (62–
64). Hingorani et al analyzed 46 PanIN (putative
precursor to invasive pancreatic cancer) and 51 con-
trol serum samples using SELDI-TOF and obtained
a parameter model comprised of 10 specific molecular
ions that was able to accurately distinguish PanIN
from control samples. Tests on a separate blinded
experiment demonstrated that the sensitivity and
specificity of this model was 90% and 87% respec-
tively, higher than 67% and 88% of CA19-9, the most
commonly used biomarker of invasive pancreatic can-
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cer (65 ).
Other strategies were also used in studying tumor
metastasis. Wu’s research group provided a model
system for proteomic studies on selected tissue sam-
ples and specific cell types by combining the LCM
and reversed phase HPLC (66 ). A number of proteins
were identified through this model by using approxi-
mately 10,000 breast cancer cells, raising the possibil-
ity of such studies on needle biopsy samples. By using
the mass-mapping technique, Kreunin et al identified
some metastasis-associated proteins including osteo-
pontin, annexin I and extracellular matrix protein 1
in a tumor metastasis model by profiling and com-
paring the component proteome of conditioned media
collected from a pair of monoclonal cell lines derived
from human breast carcinoma cell line MDA-MB-435
with different metastasis potentials (67 ).
Functional proteomics
Deciphering the signaling pathways involved in tu-
mor growth and metastasis is another major appli-
cation of cancer proteomics. These types of data
should greatly improve our understanding of the bi-
ological process of tumor development and progres-
sion, thus fostering the identification of not only single
protein-specific therapeutic targets but also pathway-
specific targets. Classical methods to study signal-
ing pathways were based on the use of specific an-
tibodies to purify known signaling proteins followed
by SDS-PAGE separation. Such studies can now be
performed by using 2DE technology to globally in-
vestigate changes in protein expression. Protein mi-
croarray technology has a great advantage to study
function on a system-wide or genome-wide basis with
a well-controlled in vitro way.
The uPA/uPAR system has been shown strongly
correlated with metastasis process. Tumor cells
acquire growth and survival advantages by over-
expressing uPA/uPAR. This makes the uPA system
an attractive target for the development of cancer
drugs that attack cancer by acting at multiple points
of the metastatic process. In a study by Ahmed et
al, a highly metastatic colon cancer cell line, HCT116
was transfected with an expression vector containing
a 5′-uPAR cDNA fragment in an antisense orienta-
tion (68 ). Using proteomic analysis, they observed
the loss of approximate 200 proteins and the quan-
titative expression differences of 141 proteins in the
antisense-clone by comparing to wild-type and mock-
transfected controls. Such global changes in pro-
tein expression not only illustrate the involvement of
uPAR-mediated signaling pathway in tumor metasta-
sis but also provide valuable information for the de-
velopment of therapeutic approaches to counter colon
cancer.
Oncofetal gene H19, which surprisingly encodes an
untranslated mRNA, has been shown to greatly stim-
ulate cancer cell growth (69 ). H19-transfected breast
epithelial cells appear to grow faster, but no molec-
ular target has been described for H19. Using 2DE
approach with 35S-methionine protein labeling, Lot-
tin et al applied proteomic profiling to study breast
mammary cells transfected with H19 oncofetal gene
(70 ). One of the major proteins regulating intracel-
lular redox metabolism, thioredoxin, was identified to
be significantly changed in protein synthesis by H19
gene transfection, suggesting that thioredoxin may be
associated with the mechanism of H19 action.
Breast cancer metastasis suppressor 1 (BRMS1)
was recently identified as a novel breast cancer metas-
tasis suppressor gene. BRMS1 significantly sup-
presses lung metastases without affecting primary
tumor growth when transfected into breast cancer
cell lines and melanoma cells (71 ). To understand
the biology behind the metastasis suppression via
BRMS1, Cicek’s group applied 2DE analysis and MS
to identify proteins differentially expressed between
highly metastatic MDA-MB-435 cells and metastasis-
suppressed BRMS1-transfected MDA-MB-435 cells
(72 ). Annexin I and alpha B-crystallin were found
expressed in vivo in lungs containing metastasized
MDA-MB-435 cells but not in normal lung tissue of
athymic mice, implicating that these two proteins are
important cellular factors in BRMS1-mediated metas-
tasis suppression.
Many gastrointestinal stromal tumors contain
oncogenic mutations of the KIT receptor tyrosine ki-
nase gene (73 ). In a research combining mutation de-
tection and analyses of 2DE and MS, Choi et al found
that the over-expression of high mobility group box 1
in gastrointestinal stromal tumors was related to the
KIT mutation, which may accelerate tumor growth
and invasion.
Post-translational modifications are important to
the function of the protein. Cells have taken advan-
tage of over 200 described post-translation modifica-
tions (74 ) to regulate the activities of their comple-
ment of proteins. In many cases, changes in post-
translational modification are the primary regulators
of protein function. Phosphoralytion is one of the
most obvious modifications that have functional ef-
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fects. Reverse-phase protein microarray is an ap-
proach suited to simultaneously screen a broad range
of pathway targets in large numbers of tumors in a
high-throughput manner (75 ). Wulfkuhle et al de-
tected the expression alteration of some key kinases
and phosphateases in 40 ovarian cancer microdis-
sected samples by using reverse-phase protein array
coupled with LCM (76 ). They spotted lysates from
40 cases of ovarian cancer tissues corresponding to
tumor histotypes and disease stages and then probed
with ERK1/2 and phosphor-ERK1/2, Akt, phosphor-
Akt S374 and phosphor-Akt T308 antibodies (76 ). To
address the issue of specificity, the authors first val-
idated all antibodies used in this study by Western
blotting against microdissected tumor tissue lysates,
and then compared protein levels of total ERK1/2
and phosphor-ERK1/2, total Akt and phosphor-Akt
between tumor histotypes and disease stages. The
results suggested that patterns in signal pathway ac-
tivation in ovarian tumors might be patient-specific
rather than type or stage specific.
Most proteomics technologies are restricted to de-
tecting changes in protein abundance, and therefore
offer only indirect evidences in protein activity. Liu et
al have developed a chemical proteomics strategy re-
ferred as activity-based protein profiling (ABPP) that
allows significant fractions of an enzyme proteome to
be analyzed in an activity-dependent fashion (77 ).
In ABPP, chemical probes covalently label the active
sites of enzyme superfamilies in a manner that pro-
vides a direct readout of changes in catalytic activity,
distinguishing functional proteases from their inactive
zymogens and/or endogenously inhibited forms (78 ).
In the experiments by Jessani et al, this strategy was
applied to quantitatively compare enzyme activities
across a panel of human breast and melanoma cancer
cell lines that differ in hormone responsiveness, inva-
siveness, and metastatic potential (37 ). Proteomes
were labeled with serine hydrolases superfamily (the
one of the largest and most diverse classes of enzymes
in the human proteome) targeted fluorophosphonate,
then separated by SDS-PAGE and visualized in-gel
by using a laser-induced fluorescence scanner. Strik-
ingly, it was found that nearly all of serine hydro-
lase activities were down-regulated in the most in-
vasive cancer lines, while the activities of a distinct
set of secreted and membrane-associated enzymes in-
cluding urokinase and enzyme KIAA1363 were up-
regulated. These results suggested that invasive can-
cers may share proteomic signatures that are more
reflective of their cellular phenotypes than tissue of
origin, and that a common set of enzymes might be-
come attractive prognostic factors or drug targets.
Complementarity of genomics and pro-
teomics
Table 2 summarizes research data of metastasis stud-
ies both in genomic and proteomic level. It is obvi-
ous that proteomic data may not be positively corre-
lated to the genomic results. Firstly, compared to ge-
nomics, proteomics at present can only study a small
fraction of total proteins as a result of its limited res-
olution. Although great improvements in proteome
study techniques have been achieved, it is still im-
possible to survey all proteins at a single experiment
due to the low abundance proteins and a variety of
post-translational modifications. Secondly, the ex-
pression profiles at the RNA and protein levels may
not be similar. It has recently been shown that there
is not necessarily direct correlation between mRNA
and protein expression levels in vivo (79 ). Nishizuka
et al compared these two levels across 60 human can-
cer cell lines by reverse-phase protein lysate microar-
ray (80 ). The mean cDNA/protein and oligo/protein
correlation coefficients for 52 proteins studied in their
experiments are from −0.10/−0.15 to +0.87/+0.88.
Among these, structure-related proteins were almost
always better correlated with mRNA levels than other
protein such as nuclear and cell-cycle proteins across
the 60 cell lines. This is actually reasonable given the
facts that post-transcriptional regulations and post-
translational modifications may occur in protein ex-
pression and synthesis. This also emphasizes the com-
plementarity of genomics and proteomics, with ge-
nomics looking at the early stages of malignant trans-
formation while proteomics focusing on the resulting
events of gene alterations and regulation. In fact, by
examining both genomics and proteomics, a biological
event such as tumor metastasis can be better under-
stood in a comprehensive and global fashion.
Metastasis models in proteomics
Before research data can be correlated with clinical
practice, a fundamental problem is the establishment
of an ideal metastastic model (81 ). So far, most of
experiments employed cell lines, biopsy or tissue sam-
ples as analytic materials. Each of them has strength
and weakness.
Cell lines have the advantages of reproducibility,
availability in large numbers, and homogeneity in
160 Geno. Prot. Bioinfo. Vol. 2 No. 3 August 2004
Cai et al.
Table 2 Summary of Differentially Expressed Proteins in Tumor Metastasis
Marker of tumor
metastasis
Characteristics of the molecule Expression level
in matastasis
Ref.
Annexin-1 Belongs to a family of closely related calcium- and
membrane-binding proteins. Annexin 1 exerts signifi-
cant effects on several physiological and pathological pro-
cesses, including cell growth, differentiation, apoptosis,
membrane fusion, and was found with expression alter-
ations in different kinds of malignant tumors.
Over expression
in non-metastatic
cell line
Increase
67
47, 48,
55, 72
Metastasis-
associated
S100A4 (Mts1)
protein
An 11-kDa calcium-binding protein strongly linked to the
formation of metastatic phenotype via regulation of cell
motility, signal transduction and invasiveness.
Increase 47
Osteopontin A glyco-phosphoprotein that is expressed and secreted by
numerous human cancers and linked with the regulation
of metastatic spread of tumor cells.
Increase 67
Extracellular ma-
trix protein 1
A secretory glycoprotein, promotes angiogenesis and is
produced by tumor cells.
Increase 67
IL-18 An essential interferon-γ (IFN-γ)-inducing factor. IL-
18 is a product of macrophages and may play a role in
metastasis by altering the microenvironment.
Increase 48
Apolipoprotein
A1
A protein that is normally expressed in liver, small in-
testine and colon carcinoma cell lines and might be a
potential marker of the tumor aggression.
Increase 46
Cytokeratin An important structural components of the epithelial cy-
toskeleton, the type of cytokeratins present in the cells is
related to their biological function. Resent studies have
indicated that cytokeratins play an important role in the
regulation of cell migration and invasion.
CK18 – Increase
CK19 – Increase
48
100
High mobility
group box 1
An intranuclear protein that interacts with several tran-
scription factors and accelerates genes related to tumor
growth and invasion.
Increase in 86% of
GISTs with KIT
mutation
51
Galectin-1 Galectins are galactoside-binding proteins that exhibit an
important function in tumor progression by promoting
cancer cell invasion and metastasis formation.
Associated with
the metastatic
phenotype
93, 96
Metalloproteinase
(MMP)
An important modulator of carcinogenesis and con-
tributes to the processes of local invasion and metastasis
by controlling the ability of a tumor to transverse tissue
boundaries.
MMP1 – Asso-
ciated with the
non-metastatic
phenotype
MMP2 – Increase
67
51
Heat shock pro-
tein (HSP)
Ubiquitously present in many cells. They are induced
by heat shock and other environmental and pathophys-
iologic stresses. Besides their putative role in thermore-
sistance, these proteins may be involved in the survival
and recovery of the cells when exposed to stressful con-
ditions. HSPs act as molecular chaperones to regulate
appropriate protein folding and packaging.
Hsp27 – Increase
Hsp60 – Decrease
Hsp90 – Increase
49
48
54
Urokinase A kind of serine protease, which can activate plasmino-
gento fibrinolysin, the latter can degrade most kinds of
extracellularmatrix. Thus construct path for metastasis
from the extracellular local lysis region.
Increased enzyme
activity
37
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Table 2 Continued
Marker of tumor
metastasis
Characteristics of the molecule Expression level
in matastasis
Ref.
Tropomyosin Tropomyosins (TMs) are ubiquitous actin-binding pro-
teins found in muscle and nonmuscle cells. In nonmuscle
cells, they are associated with cytoskeletal actin in micro-
filaments. Changes of expression level of TMs may lead
to a change in cell motility, which is considered to be one
of the important characteristics of high-metastatic tumor
cells.
TM – Increase
TM1 – Increase
TM2 – Decrease
48
84, 101
102
cell lineage. Lots of experiments attempted to iden-
tify biomarkers or obtain biological insights of tumor
metastatsis by comparing the protein expressions be-
tween cell lines that differ in metastatic potential (Ta-
ble 1). Tang and his co-workers have developed a
stepwise metastatic human HCC model system in-
cluding a low metastatic subclone MHCC97L, a high
metastatic subclone MHCC97H, and two even higher
metastatic potential cell lines HCCLM3 and HC-
CLM6 (82 ). With this model system, interesting re-
sults were obtained in the search for HCC metastasis-
related chromosomes/proteins/genes. However, no
cell lines in culture are fully representative of tumor in
vivo. Researches have proved that without a support-
ing tumor microenviroment, only cancer cells alone
are not enough to confer metastatic status (19 , 81 )
and that tumor-microenviromental interaction has a
decisive role in controlling local cancer growth, inva-
sion and distant metastasis (83 ). Jessani et al ana-
lyzed enzyme activity profiles of human breast cancer
cell line MDA-MB-231 when grown in culture and as
orthotopic xenograft tumors in nude mice (84 ). Cells
isolated from tumors exhibited dramatic posttrans-
lational up-regulation of urokinase plasminogen acti-
vator and down-regulation of the glycolytic enzyme
phosphofructiokinase. This result indicates that spe-
cific host components have a contribution to tumor
biology.
Biopsies and tumor blocks are ideal experiment
materials in cancer research. The data derived from
such samples exhibit the real condition of cancer de-
velopment. But a major difficulty is the cellular het-
erogeneity of tumors. Besides cancer cells, tumor
tissues also contain other cell types, including my-
oepithelial cells, fibroblasts and endothelial cells. It
is possible that a proteomics analysis may be con-
founded by opposed protein changes in different cell
types and then the sensitivity of the analysis may be
greatly reduced. LCM technology may provide help,
enabling researchers to collect specific cell types from
a tissue sample. Using LCM researchers can obtain
more accurate representation of cells and make more
accurate comparisons of protein expression between
specimens. LCM is extremely useful when only a few
tumor cells exist in a solid tissue such as metastaic
lymph nodes. LCM technique has been successfully
coupled with 2DE (85 , 86 ), LC/MS (87 , 88 ), SELDI
(60 , 61 ) and protein microarray (76 ) in proteomic
analyses.
Other commonly used metastatic models were
formed by inoculating tumor cells or tissue blocks to
nude mice to develop visible metastases at secondary
sites. Those metastasis-associated molecules then
were identified based on these models. These assays
are hardly able to clarify which steps in the metastatic
process are affected by specific molecules (89 , 90 ) and
which are metastatic-related and metastatic-induced
factors.
However, endeavors have continually been made
for establishing an ideal model for tumor metasta-
sis research. Recently Hingorani and his colleagues
developed a mouse model of human pancreatic in-
traepithelial neoplasias (PanIN) to investigate the de-
velopment of invasive and metastasis of pancreatic
cancer (65 ). It has been reported that activating
mutations in the KRAS proto-oncogene were found
in over 90% of invasive pancreatic ductal adenocar-
cinoma and were thought to represent an initiating
event (91 ). This raises a hypothesis that physiologi-
cal levels of oncogenic KRAS would serve to initiate
pancreatic cancer. The authors targeted expressed
oncogenic KRAS to progenitor cells of mouse pancreas
and demonstrated that the endogenous expression of
KRAS initiated the development of PanINs identical
to all three stages found in the cognate human condi-
tion (65 ). Using this model, researchers can investi-
gate the entire progression of pancreatic ductal ade-
nocarcinoma from preinvasive neoplasias to invasive
and metastatic disease.
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Conclusion
Despite of many molecular factors having been iden-
tified as contributing to the formation of detectable
metastases (Table 2), the road of unveiling the mech-
anism of tumor metastasis is still far. The relevance
of these data to clinical practice still has to be es-
tablished. Indeed, none of the potential markers de-
scribed so far by proteomics is routinely used by clin-
icians for either diagnosis, treatment choice or prog-
nosis (56 ). This highlights the necessity to use high-
throughput systematic approaches to rapidly identify
more metastasis-related factors that can be consid-
ered in an integrated way.
Nevertheless, current research data demonstrate
the value of proteomic analysis for understanding the
molecular mechanism involved in metastasis activity.
A combined approach is expected to become the basis
for the development of the mechanistic studies. Fur-
ther evaluation and characterization of the genomic
and proteomic variations may lead to the identifica-
tion of biomarkers that can be specifically applied
to metastatic assay and diagnosis in clinic. In ad-
dition, integration of proteomics with other experi-
mental disciplines, particularly biochemistry, cell biol-
ogy, molecular genetics and chemistry, will continue to
extend the application of proteomics in investigating
tumor metastasis. The technological advances in pro-
tein detection and identification are surely also crit-
ical. Rapidly progressing technologies will promote
future development in the field of cancer proteomics.
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